Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis

The Lancet

Volumn 384, Issue 9938, 2014, Pages 164-172

  Cortazar, Patricia ^a   Zhang, Lijun ^a   Untch, Michael ^b   Mehta, Keyur ^c   Costantino, Joseph P ^d   Wolmark, Norman ^d   Bonnefoi, Hervé ^e   Cameron, David ^f   Gianni, Luca ^g   Valagussa, Pinuccia ^h   Swain, Sandra M ⁱ   Prowell, Tatiana ^a   Loibl, Sibylle ^c   Wickerham, D Lawrence ^d   Bogaerts, Jan ^j   Baselga, Jose ^k   Perou, Charles ^l   Blumenthal, Gideon ^a   Blohmer, Jens ^m   Mamounas, Eleftherios P ⁿ   Bergh, Jonas ^o   Semiglazov, Vladimir ^p   Justice, Robert ^a   Eidtmann, Holger ^q   Paik, Soonmyung ^d   Piccart, Martine ^r   Sridhara, Rajeshwari ^a   Fasching, Peter A ^s   Slaets, Leen ^j   Tang, Shenghui ^a   Gerber, Bernd ^t   Geyer, Charles E ^u   Pazdur, Richard ^a   Ditsch, Nina ^v   Rastogi, Priya ^d   Eiermann, Wolfgang ^v   Von Minckwitz, Gunter ^c   more..

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HELIOS Klinikum   (Germany)

^c GERMAN BREAST GROUP   (Germany)

^d NSABP Foundation Inc   (United States)

^e INSTITUT BERGONIÉ   (France)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h Fondazione Michelangelo   (Italy)

ⁱ WASHINGTON HOSPITAL CENTER   (United States)

^j EORTC DATA CENTER   (Belgium)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l UNIVERSITY OF NORTH CAROLINA   (United States)

^m St Gertrauden Hospital   (Germany)

ⁿ M D ANDERSON CANCER CENTER ORLANDO   (United States)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^p N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^q UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^r JULES BORDET INSTITUTE   (Belgium)

^s UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^t ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^u VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^v LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISEASE ERADICATION; DISEASE FREE SURVIVAL; EMBASE; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; LONG TERM CARE; MEDLINE; OVERALL SURVIVAL; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; CANCER PATIENT; DISEASE ASSOCIATION; DISEASE CLEARANCE; HAZARD RATIO; INFLAMMATORY BREAST CANCER; OUTCOME ASSESSMENT; PATHOLOGY; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84904188903     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62422-8     Document Type: Article

References (28)

1. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366: 2438-41.
2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L. Preoperative chemotherapy in operable breast cancer. Lancet 1993; 341: 1485.
3. Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer-10-year survival data after chemotherapy and hormone therapy. Br J Cancer 1997; 76: 1099-105.
4. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-81.
5. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007; 2: CD005002.
6. Burzykowski T. An ordinal surrogate for a survival true endpoint. In: Burzykowski T, Molengerghs G, Buyse M, eds. The evaluation of surrogate endpoints. New York, NY: Springer, 2005.
7. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009; 27: 2938-45.
8. Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fl uorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27: 2474-81.
9. Bonnefoi H, Piccart M, Bogaerts J, et al, on behalf of the EORTC 10994/BIG 1-00 Study Investigators. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011; 12: 527-39.
10. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-85.
11. von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline-And taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28: 2015-23.
12. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28: 2024-31.
13. von Minckwitz G, Kümmel S, Vogel P, et al, and the German Breast Group. Neoadjuvant vinorelbine-capecitabine versus docetaxeldoxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-51.
14. von Minckwitz G, Kümmel S, Vogel P, et al, and the German Breast Group. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552-62.
15. von Minckwitz G, Blohmer JU, Raab G, et al, and the German Breast Group. In vivo chemosensitivity-Adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63.
16. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-84.
17. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
18. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-85.
19. Bear HD, Anderson S, Brown A, et al, and the National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-74.
20. Untch M, Fasching PA, Konecny GE, et al, and the Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer-results at the time of surgery. Ann Oncol 2011; 22: 1988-98.
21. Untch M, von Minckwitz G, Konecny GE, et al, and the Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 2011; 22: 1999-2006.
22. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011; 29: 3351-57.
23. von Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-Adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-56.
24. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578-81.
25. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007; 25: 2650-55.
26. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-804.
27. Buyse M, Burzykowski T, Michiels S, Carroll K. Individual-And trial-level surrogacy in colorectal cancer. Stat Methods Med Res 2008; 17: 467-75.
28. US Center for Drug Evaluation and Research. Guidance for industry: pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. May, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM305501.pdf (accessed Jan 22, 2014).